Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Similares em SciELO
Compartilhar
Revista Portuguesa de Pneumologia
versão impressa ISSN 0873-2159
Rev Port Pneumol v.14 n.6 Lisboa dez. 2008
Estudo de polimorfismos genéticos do HLA (classes I e II) e do TNF-á em doentes com sarcoidose
António Morais 1
Helena Alves 2
Bruno Lima 2
Luís Delgado 3
Ricardo Gonçalves 2
Sandra Tafulo 2
Resumo
Introdução: A susceptibilidade genética na ocorrência da sarcoidose é sugerida por alguns factores, nomeadamente pela observação de casos de agregação familiar e a associação da raça a diferentes tipos de incidência e gravidade da doença. Vários estudos têm evidenciado a associação da classe I e especialmente da classe II do sistema HLA com a susceptibilidade à sarcoidose.
Objectivos: Estudo dos polimorfismos genéticos da classe I e II do sistema HLA e do TNF -á num grupo de doentes com sarcoidose, nomeadamente a sua influência na susceptibilidade, apresentação clínica e evolução da doença.
Material e métodos: Foram incluídos 104 doentes com sarcoidose, tendo sido estudadas a apresentação clínica, funcional, radiológica e os resultados do LBA. Foram usados métodos de biologia molecular na genotipagem do HLA -A*, B*, C*, DRB1*, DQB1* e TNF -á. O ADN foi extraído do sangue periférico e foram usados os métodos PCR -SSP e PCR -reverse hibridization. As frequências alélicas foram comparadas com controlos da mesma região geográfica pelo teste ÷2, sendo usado o teste Kruskal -Wallis para variáveis contínuas.
Resultados: Comparativamente com os controlos, os doentes incluídos apresentavam frequências aumentadas de: B*08 (10,6% vs 6,1%), OR=1,8, IC=[1,1;3,1], p=0,02; DRB1*12 (4,3% vs 1,7%), OR=2,63, IC=[1,1;6,1], p=0,03. Os doentes com eritema nodoso apresentaram aumento das frequências alélicas de DRB1*03 (28% vs 9,3%), RR=2,39, IC=[1,5;3,8], pc=0,01 e DQB1*02 (38% vs 18%), RR=2,1, IC=[1,3;3,3], pc=0,02. O alelo DQB1*03 está diminuído nos doentes que apresentam síndroma ventilatória obstrutiva, RR=0,53, IC=[0,3;0,9],pc=0,05. O alelo DRB1*15 encontra -se significativamente associado quer à síndroma ventilatória restritiva quer à diminuição da transferência alveolocapilar (21,1% vs 6,6%), RR=2,46, IC=[1,35;4,48], p=0,01 e (18,1% vs 3,8%), RR=1,87, pc=0,05, respectivamente. Por sua vez, o genótipo A/A (high) do TNF -á apresentou uma frequência aumentada (p=0,04) nos doentes com eritema nodoso.
Conclusões: Os resultados obtidos adicionam evidência ao facto de, quer a classe I quer a classe II do sistema HLA influenciarem a susceptibilidade, o tipo de apresentação, o grau de gravidade e a evolução na sarcoidose. Por outro lado, o eritema nodoso parece relacionar -se com o genótipo de elevada produção de TNF -á, associação esta já anteriormente descrita.
Palavras-chave: Sacordoise, genética, HLA.
HLA class I and II and TNF-á gene polymorphisms in sarcoidosis patients
Abstract
Introduction: Several factors suggest a genetic predisposition to sarcoidosis, namely the recognition of race as a risk factor and the occurrence of familial clustering of cases. Several studies have reported an association of sarcoidosis and HLA class I and especially class II alleles in different populations.
Aim: HLA class I, class II and TNF-á genotyping in a group of sarcoidosis patients and its relation with clinical presentation and outcome.
Material and methods: A total of 104 sarcoidosis patients were included. Clinical presentation, functional, radiology, BAL findings and organ involvement were studied. HLA A*, -B*, -C*, DRB1*, DQB1* and TNF-á were genotyped by molecular biology methods. DNA was extracted from peripheral blood and PCR-SSP and PCR-reverse hybridisation methods were used. Allele frequencies were compared with controls from the same region. The X2 test was used for discrete values and the Kruskal-Wallis test for continuous values.
Results: When patients were compared with controls we noticed increased frequencies of B*08 (10.6% vs. 6.1%), O.R.=1.8, C.I.=[1.1;3.1], p=0.02; DRB1*12 (4.3% vs. 1.7%), O.R.=2.63, C.I.=[1.1;6.1], p=0.03. Patients with erythema nodosum have increased frequencies of the alleles DRB1*03 (28% vs. 9.3%), R.R.=2.39, C.I.=[1.5;3.8], pc=0.01 and DQB1*02 (38% vs. 18%), R.R.=2.1, C.I.=[1.3;3.3], pc=0.02. Allele DQB1*03 is decreased in patients with obstructive pattern R.R.=0.53, C.I.=[0.3;0.9], pc=0.05. Allele DRB1*15 is related to restrictive pattern and reduced diffusion capacity (21.1% vs. 6.6%), R.R.=2.46, C.I.=[1.35;4.48], p=0.01 and (18.1% vs. 3.8%), R.R.=1.87, pc= 0.05 respectively. The TNF-á A/A (high) genotype is significantly associated with erythema nodosum (p=0.04).
Conclusions: These data add support to the genetic association of HLA class I and II with sarcoidosis in terms of susceptibility, type of presentation, severity and outcome. Moreover as previously described in other populations, the TNF-á A/A (high) genotype has a significant association with erythema nodosum.
Key-words: Sarcoidosis, genetics, HLA.
Texto completo disponível apenas em PDF.
Full text only available in PDF format.
Bibliografia / Bibliography
1. Hunninghake GW, Costabel U, Ando M. ATS/ERS/WASOG Statement on Sarcoidosis. Am J Respir Crit Care Med 1999; 160:736 -55. [ Links ]
2. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153 -65.
3. Baughman RP, Lower EE, du Bois R. Sarcoidosis. Lancet 2003; 361: 1111.
4. Iannuzzi MC, Rybicki BA. Genetics ofn sarcoidosis; candidate genes and genome scans. Proc Am Thorac Soc 2007; (4):108 -16.
5. Rybicki BA, Iannuzzi MC, Frederick MM et al. Familial aggregation of sarcoidosis. A case control etiologic study of sarcoidosis (ACCESS). Am J Repir Crit Care Med 2001; 164: 2085.
6. Klein J, Sato A. The HLA System. N Engl J Med, 2000; 343, 10: 702 -709
7. Rybicki BA, Iannuzzi MC. Sarcoidosis and human leucocyte antigen class I and II genes. Am J Respir Crit Care Med 2004; 169: 665 -666.
8. Brewerton D, Cockburn C, James D, et al. HLA antigens in sarcoidosis. Clin Exp Immunol 1977 ; 27 : 227-229.
9. Olenchock S, Heise E, Marz J, et al. HLA -B8 in sarcoidosis. Ann Allergy 1981 ; 47 : 151 -153.
10. Lenhart K, Kolek V, Bartova A. HLA antigens associated with sarcoidosis. Dis Markers 1990 ; 8 : 23 -29.
11. Dubaniewicz A, Szczerkowska Z. HLA -A,B,C antigens in pulmonary sarcoidosis in Polish population. Arch Immunol Ther Exp (Warz) 1999; 47 (1): 55 -9.
12. Pasturenzi L, Martinetti M, Cuccia M. HLA class I, II, III polymorphism in Italian patients with sarcoidosis. Chest 1993 Oct; 104 (4): 1170 -5.
13. Martinetti M, Tinelli C, Kolek V, et al. The sarcoidosis map': a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995; 152:557 -64.
14. Sharma S, Balamurugan A, Pandey R, et al. Human leukocyte antigen DR alleles influence the clinical course of pulmonary sarcoidosis in asian Indians. Am J Respir Cell Mol Biol 2003; 29: 225 -31.
15. Dubaniewicz A, Szczerkowska Z, Hoppe A. Comparative analysis of HLA class I antigens in pulmonary sarcoidosis and tuberculosis in the same ethnic group. Mayo Clin Proc 2003; 78(4):436 -42.
16. McIntyre J, Mckee K, Loadholt C, et al. Increased HLA-B7 antigen frequency in South Caroline blacks in association with sarcoidosis. Transplant Proc 1977; 9: 173 -176.
17. Rutherford RM, Brutshe MH, Kearns M, et al. HLA -DR2 predicts susceptibility and disease chronicity in Irish sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21(3):191 -8.
18. Smith M, Turton C, Mitchell D, et al. Association of HLA -B8 with spontaneous resolution in sarcoidosis. Thorax 1981; 36: 296 -298.
19. Grunewald J, Eklund A, Olerup O. Human luekocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med 2004; 169: 696 -702.
20. Ishihara M, Inoko H, Suzuki K, et al. HLA class II genotyping of sarcoidosis patients in Hokkaido by PCR- -RFLP. Jpn J Ophthalmol 1996; 40: 540 -3.
21. Ishihara M, Ishida T, Inoko H, et al. HLA serological and class II genotyping in sarcoidosis patients in Japan. Jpn J Ophthalmol 1996; 40: 86 -94.
22. Nowack D, Goebel KM. Genetic aspects of sarcoidosis. ClassII histocompatibility antigens and a family study. Arch Intern Med 1987; 147: 481 -3.
23. Rossman MD, Thomson B, Frederick M, et al. HLA -DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003; 73: 720 -35.
24. Iannuzzi M, Maliarik M, Poisson L, et al. Sarcoidosis susceptibility and resistance HLA -DQB1 alleles in African Americans. Am J Respir Crit Care Med 2003; 1670:1225 -31.
25. Grutters J, Sato H, Welsh K, et al. Am J Respir Cell Mol Biol 2003; 29:S59 -S62.
26. Voorter CE, Drent M, Van den Berger -Loonen EM. Severe pulmonary sarcoidosis is strongly associated with the haplotype HLA -DQB1*0602 -DRB1*150101. Hum Immunol 2005; 66(7):826 -35.
27. Rybicki BA, Maliarik MJ, Poisson LM. The major histocompatibility complex gene region and sarcoidosis susceptibility in African Americans. Am J Respir Crit Care Med 2003; 167: 444 -449.
28. Sato H, Grutters J, Pantelidis P. et al. HLA DQB1*0201: a marker for good prognosis in british and dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002; 27:406 -11.
29. Grutters JC, Ruven HJT, Sato H, et al. MHC haplotype analysis in Dutch sarcoidosis patients presenting with Löfgrens syndrome. In: Grutters JC (Ed.). Genetic polymorphisms and phenotypes in sarcoidosis. Utrecht, Thesis University Utrech, 2003: 85 -96.
30. Mrazek F, Holla LI, Hutyrova B, et al. Association of tumor necrosis factor -alpha, lymphotoxin -alpha and HLA -DRB1 gene polymorphisms with Lofgrens syndrome in Czech patients with sarcoidosis. Tissue Antigens 2005; 65(2):163 -71.
31. Berlin M, Fogdell -Hahn A, Olerup O, et al. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997;156:1601 -5.
32. Grutters JC, Sato H, Pantelidis P, et al. Analysis of IL -6 and IL1A gene polymorphisms in UK and Dutch patients with sarcoidosis. Sarcoidosis Vas Diffuse Lung Dis 2003; 20(1):20 -7.
33. Spagnolo P, du Bois RM. Genetics of sarcoidosis. Clinics in Dermatology 2007; 25:242 -9.
34. Somoskovi A, Zissel G, Seitzer U, et al. Polymorphisms at position 308 in the promoter region of the TNF-alpha and in the first intron of the TNF-beta genes and spontaneous and lipopolysaccharide induced TNF -alpha release in sarcoidosis. Cytokine 1999; 11 (11): 882 -887.
35. Grutters JC, Sato H, Pantelidis P, et al. Increased frequency of the uncommon tumor necrosis factor--857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 2002; 165: 1119--1124.
36. Grutters JC, Ruven HJT, Sato H, et al. TNF promotor haplotypes associate with clinical phenotypes and prognosis in sarcoidosis. In: Grutters JC (Ed.). Genetic polymorphisms and phenotypes in sarcoidosis. Utrecht, Thesis University Utrecht; 2003: 49 -66.
37. Mrazek F, Holla LI, Hutyrova B, Znojil V, Vasku A, Kolek V, Welsh KI, Vacha J, du Bois RM, Petrek M. Association of tumor necrosis factor -á, lymphotoxin-á and DRB1 gene polymorphisms with Löfgrens syndrome in Czech patients with sarcoidosis. Tissue Antigens 2005; 65:163 -717
38. Seitzer U, Swider C, Stuber F, et al. Tumour necrosis factor alpha promotor gene polymorphism in sarcoidosis. Cytokine 1997; 9: 787 -90.
39. Martinetti M, Luisetti M, Cuccia M. HLA and sarcoidosis: new pathogenic insights. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19.
40. Labunski S, Posern G, Ludwig S, et al. Tumour necrosis factor -alpha promoter polymorphism in erythema nodosum. Acta Derm Venereol 2001; 81(1): 18--21.
41. Yamaguchi E, Itoh A, Hizawa N, et al. The gene polymorphism of tumour necrosis factor -beta, but not that of tumour necrosis factor -alpha, is associated with prognosis of sarcoidosis. Chest 2001; 119 (3): 753-61.
42. Takashigue N, Naruse TK, Matsumori A, et al. Genetic polymorphisms at tumour necrosis factor loci (TNFA and TNFB) in cardiac sarcoidosis. Tissue Antigens 1999; 54(2):191-3.
1 Serviço de Pneumologia do Hospital São João, Porto / Pulmonology Unit, Hospital São João, Porto
2 Centro de Histocompatibilidade do Norte / Histocompatability Centre of the North
3 Serviço de Imunologia da Faculdade de Medicina do Porto / Pulmonology Unit, Porto Faculty of Medicine